<p>Prestige Consumer（紐約證券交易所代碼：PBH）將於 2026 年 2 月 5 日（星期四）發佈季度財報。以下是投資者在公告前的簡要概述。</p>
<p>分析師預計 Prestige Consumer 的 <strong>每股收益</strong>（EPS）為 1.16 美元。</p>
<p>Prestige Consumer 的公告備受期待，投資者希望看到超出預期的消息以及對下個季度的積極指引。</p>
<p>值得新投資者注意的是，指引可能是股價波動的關鍵因素。</p>
<h3>之前財報的表現</h3>
<p>該公司在上個季度的每股收益超出預期 0.09 美元，導致次日股價下跌 2.3%。</p>
<p>以下是 Prestige Consumer 過去表現及其價格變化的概覽：</p>
<table>
<thead>
<tr>
<th><strong>季度</strong></th>
<th align="right"><strong>2026 年第二季度</strong></th>
<th align="right"><strong>2026 年第一季度</strong></th>
<th align="right"><strong>2025 年第四季度</strong></th>
<th align="right"><strong>2025 年第三季度</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS 預估</strong></td>
<td align="right">0.98</td>
<td align="right">1.00</td>
<td align="right">1.29</td>
<td align="right">1.16</td>
</tr>
<tr>
<td><strong>EPS 實際</strong></td>
<td align="right">1.07</td>
<td align="right">0.95</td>
<td align="right">1.32</td>
<td align="right">1.22</td>
</tr>
<tr>
<td><strong>價格變化 %</strong></td>
<td align="right">-2.00</td>
<td align="right">-3.00</td>
<td align="right">0.00</td>
<td align="right">0.00</td>
</tr>
</tbody>
</table>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770235267_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="eps graph" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770235267_0.png"/></p>
<h3>Prestige Consumer 股價分析</h3>
<p>截至 2 月 3 日，Prestige Consumer 的股票交易價格為 64.43 美元。在過去 52 周內，股價下跌了 23.45%。鑑於這些回報通常為負，長期股東在此次財報發佈前可能感到不滿。</p>
<h3>分析師對 Prestige Consumer 的觀察</h3>
<p>瞭解市場情緒和行業內的預期對投資者至關重要。本分析深入探討了 Prestige Consumer 的最新見解。</p>
<p>Prestige Consumer 共收到 2 個分析師評級，普遍評級為買入。平均一年期目標價為 77.0 美元，暗示潛在上漲 19.51%。</p>
<h3>行業同行評級比較</h3>
<p>在此比較中，我們探討了 Tarsus Pharmaceuticals、Supernus Pharmaceuticals 和 Ligand Pharmaceuticals 這三家知名行業公司的分析師評級和平均一年期目標價，提供對其相對錶現預期和市場定位的見解。</p>
<ul>
<li>分析師目前對 Tarsus Pharmaceuticals 的評級為跑贏大盤，平均一年期目標價為 100.0 美元，暗示潛在上漲 55.21%。</li>
<li>分析師目前對 Supernus Pharmaceuticals 的評級為中性，平均一年期目標價為 55.0 美元，暗示潛在下跌 14.64%。</li>
<li>分析師目前對 Ligand Pharmaceuticals 的評級為買入，平均一年期目標價為 242.14 美元，暗示潛在上漲 275.82%。</li>
</ul>
<h3>同行分析總結</h3>
<p>同行分析總結提供了 Tarsus Pharmaceuticals、Supernus Pharmaceuticals 和 Ligand Pharmaceuticals 的關鍵指標快照，揭示它們在行業中的相對地位。這些指標為其市場地位和比較表現提供了有價值的見解。</p>
<table>
<thead>
<tr>
<th>公司</th>
<th>共識</th>
<th>收入增長</th>
<th>毛利潤</th>
<th>股本回報率</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prestige Consumer</td>
<td>買入</td>
<td>-3.41%</td>
<td>1.5158 億美元</td>
<td>2.29%</td>
</tr>
<tr>
<td>Tarsus Pharmaceuticals</td>
<td>跑贏大盤</td>
<td>146.68%</td>
<td>1.1039 億美元</td>
<td>-3.77%</td>
</tr>
<tr>
<td>Supernus Pharmaceuticals</td>
<td>中性</td>
<td>9.34%</td>
<td>1.7314 億美元</td>
<td>-4.27%</td>
</tr>
<tr>
<td>Ligand Pharmaceuticals</td>
<td>買入</td>
<td>122.85%</td>
<td>1.1166 億美元</td>
<td>13.19%</td>
</tr>
</tbody>
</table>
<p>關鍵要點：</p>
<p>Prestige Consumer 在收入增長和毛利潤方面排名靠後，而在股本回報率方面排名中等。</p>
<h3>更好地瞭解 Prestige Consumer</h3>
<p>Prestige Consumer Healthcare 是最大的純粹非處方醫療保健提供商之一。它擁有多樣化的產品組合，涵蓋了細分消費健康類別中的領先品牌。Prestige 的主要品牌包括 Clear Eyes（緩解紅眼）、Dramamine（緩解暈動病）、Monistat（陰道抗真菌藥）和 Summer's Eve（女性衞生用品），其許多品牌在類別中享有領導地位，並獲得醫療專業人士的推薦。該公司主要在北美運營，約 85% 的總收入來自該地區，其餘銷售來自澳大利亞、新西蘭和某些亞洲市場。</p>
<h3>分析 Prestige Consumer 的財務表現</h3>
<p><strong>市值分析：</strong> 公司的市值低於行業基準，反映出與同行相比規模較小。這一定位可能受到增長預期或運營能力等因素的影響。</p>
<p><strong>負面收入趨勢：</strong> 對 Prestige Consumer 的財務數據進行三個月的審查顯示出挑戰。截至 2025 年 9 月 30 日，該公司的收入增長約下降了 <strong>-3.41%</strong>，反映出頂線收益的減少。與同行相比，收入增長落後於行業同行。該公司的增長率低於醫療保健行業同行的平均水平。</p>
<p><strong>淨利潤率：</strong> Prestige Consumer 的財務實力體現在其卓越的淨利潤率上，超過行業平均水平。該公司的淨利潤率達到 <strong>15.4%</strong>，展現出強大的盈利能力和有效的成本管理。</p>
<p><strong>股本回報率（ROE）：</strong> 該公司的 ROE 表現突出，超過行業平均水平。其 ROE 達到 <strong>2.29%</strong>，展現出有效利用股本的能力。</p>
<p><strong>資產回報率（ROA）：</strong> 該公司的 ROA 表現突出，超過行業平均水平。其 ROA 達到 <strong>1.23%</strong>，展現出有效利用資產的能力。</p>
<p><strong>債務管理：</strong> 該公司保持平衡的債務管理，債務與股本比率低於行業標準，達到 <strong>0.57</strong>。</p>
<p>要跟蹤 Prestige Consumer 的所有財報發佈，請訪問我們網站的財報日曆。</p>
<p><em>本文由 Benzinga 的自動內容引擎生成，並由編輯審核。</em></p>

普雷斯蒂奇

<p>Prestige Consumer（紐約證券交易所代碼：PBH）定於 2026 年 2 月 5 日發佈季度財報，分析師預計每股收益（EPS）為 1.16 美元。該公司此前超出每股收益預期 0.09 美元，但股價隨後下跌了 2.3%。目前股價為 64.43 美元，Prestige Consumer 的股票在過去一年中下跌了 23.45%。分析師對該股票的評級為 “買入”，一年目標價為 77.0 美元，顯示出 19.51% 的潛在上漲空間。該公司在收入增長方面面臨挑戰，報告顯示下降了 3.41%，但保持了 15.4% 的強勁淨利潤率</p>

<p>Prestige Consumer (NYSE: PBH) will release its quarterly earnings report on Thursday, 2026-02-05. Here's a brief overview for investors ahead of the announcement.</p>
<div class="lb-trans"><p>Prestige Consumer（紐約證券交易所代碼：PBH）將於 2026 年 2 月 5 日（星期四）發佈季度財報。以下是投資者在公告前的簡要概述。</p>
</div><p>Analysts anticipate Prestige Consumer to report an <strong>earnings per share</strong> (EPS) of $1.16.</p>
<div class="lb-trans"><p>分析師預計 Prestige Consumer 的 <strong>每股收益</strong>（EPS）為 1.16 美元。</p>
</div><p>The announcement from Prestige Consumer is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<div class="lb-trans"><p>Prestige Consumer 的公告備受期待，投資者希望看到超出預期的消息以及對下個季度的積極指引。</p>
</div><p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<div class="lb-trans"><p>值得新投資者注意的是，指引可能是股價波動的關鍵因素。</p>
</div><h3>Performance in Previous Earnings</h3>
<div class="lb-trans"><h3>之前財報的表現</h3>
</div><p>The company's EPS beat by $0.09 in the last quarter, leading to a 2.3% drop in the share price on the following day.</p>
<div class="lb-trans"><p>該公司在上個季度的每股收益超出預期 0.09 美元，導致次日股價下跌 2.3%。</p>
</div><p>Here's a look at Prestige Consumer's past performance and the resulting price change:</p>
<div class="lb-trans"><p>以下是 Prestige Consumer 過去表現及其價格變化的概覽：</p>
</div><table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th align="right"><strong>Q2 2026</strong></th>
<th align="right"><strong>Q1 2026</strong></th>
<th align="right"><strong>Q4 2025</strong></th>
<th align="right"><strong>Q3 2025</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td align="right">0.98</td>
<td align="right">1.00</td>
<td align="right">1.29</td>
<td align="right">1.16</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td align="right">1.07</td>
<td align="right">0.95</td>
<td align="right">1.32</td>
<td align="right">1.22</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td align="right">-2.00</td>
<td align="right">-3.00</td>
<td align="right">0.00</td>
<td align="right">0.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th><strong>季度</strong></th>
<th align="right"><strong>2026 年第二季度</strong></th>
<th align="right"><strong>2026 年第一季度</strong></th>
<th align="right"><strong>2025 年第四季度</strong></th>
<th align="right"><strong>2025 年第三季度</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS 預估</strong></td>
<td align="right">0.98</td>
<td align="right">1.00</td>
<td align="right">1.29</td>
<td align="right">1.16</td>
</tr>
<tr>
<td><strong>EPS 實際</strong></td>
<td align="right">1.07</td>
<td align="right">0.95</td>
<td align="right">1.32</td>
<td align="right">1.22</td>
</tr>
<tr>
<td><strong>價格變化 %</strong></td>
<td align="right">-2.00</td>
<td align="right">-3.00</td>
<td align="right">0.00</td>
<td align="right">0.00</td>
</tr>
</tbody>
</table>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770235267_0.png" alt="eps graph" original-src="https://www.benzinga.com/files/images/story/2026/1770235267_0.png"/></p>
<h3>Prestige Consumer Share Price Analysis</h3>
<div class="lb-trans"><h3>Prestige Consumer 股價分析</h3>
</div><p>Shares of Prestige Consumer were trading at $64.43 as of February 03. Over the last 52-week period, shares are down 23.45%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release.</p>
<div class="lb-trans"><p>截至 2 月 3 日，Prestige Consumer 的股票交易價格為 64.43 美元。在過去 52 周內，股價下跌了 23.45%。鑑於這些回報通常為負，長期股東在此次財報發佈前可能感到不滿。</p>
</div><h3>Analyst Observations about Prestige Consumer</h3>
<div class="lb-trans"><h3>分析師對 Prestige Consumer 的觀察</h3>
</div><p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Prestige Consumer.</p>
<div class="lb-trans"><p>瞭解市場情緒和行業內的預期對投資者至關重要。本分析深入探討了 Prestige Consumer 的最新見解。</p>
</div><p>A total of 2 analyst ratings have been received for Prestige Consumer, with the consensus rating being Buy. The average one-year price target stands at $77.0, suggesting a potential 19.51% upside.</p>
<div class="lb-trans"><p>Prestige Consumer 共收到 2 個分析師評級，普遍評級為買入。平均一年期目標價為 77.0 美元，暗示潛在上漲 19.51%。</p>
</div><h3>Comparing Ratings Among Industry Peers</h3>
<div class="lb-trans"><h3>行業同行評級比較</h3>
</div><p>In this comparison, we explore the analyst ratings and average 1-year price targets of Tarsus Pharmaceuticals, Supernus Pharmaceuticals and Ligand Pharmaceuticals, three prominent industry players, offering insights into their relative performance expectations and market positioning.</p>
<div class="lb-trans"><p>在此比較中，我們探討了 Tarsus Pharmaceuticals、Supernus Pharmaceuticals 和 Ligand Pharmaceuticals 這三家知名行業公司的分析師評級和平均一年期目標價，提供對其相對錶現預期和市場定位的見解。</p>
</div><ul>
<li>Analysts currently favor an Outperform trajectory for Tarsus Pharmaceuticals, with an average 1-year price target of $100.0, suggesting a potential 55.21% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Supernus Pharmaceuticals, with an average 1-year price target of $55.0, suggesting a potential 14.64% downside.</li>
<li>Analysts currently favor an Buy trajectory for Ligand Pharmaceuticals, with an average 1-year price target of $242.14, suggesting a potential 275.82% upside.</li>
</ul>
<div class="lb-trans"><ul>
<li>分析師目前對 Tarsus Pharmaceuticals 的評級為跑贏大盤，平均一年期目標價為 100.0 美元，暗示潛在上漲 55.21%。</li>
<li>分析師目前對 Supernus Pharmaceuticals 的評級為中性，平均一年期目標價為 55.0 美元，暗示潛在下跌 14.64%。</li>
<li>分析師目前對 Ligand Pharmaceuticals 的評級為買入，平均一年期目標價為 242.14 美元，暗示潛在上漲 275.82%。</li>
</ul>
</div><h3>Peer Analysis Summary</h3>
<div class="lb-trans"><h3>同行分析總結</h3>
</div><p>The peer analysis summary provides a snapshot of key metrics for Tarsus Pharmaceuticals, Supernus Pharmaceuticals and Ligand Pharmaceuticals, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<div class="lb-trans"><p>同行分析總結提供了 Tarsus Pharmaceuticals、Supernus Pharmaceuticals 和 Ligand Pharmaceuticals 的關鍵指標快照，揭示它們在行業中的相對地位。這些指標為其市場地位和比較表現提供了有價值的見解。</p>
</div><table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prestige Consumer</td>
<td>Buy</td>
<td>-3.41%</td>
<td>$151.58M</td>
<td>2.29%</td>
</tr>
<tr>
<td>Tarsus Pharmaceuticals</td>
<td>Outperform</td>
<td>146.68%</td>
<td>$110.39M</td>
<td>-3.77%</td>
</tr>
<tr>
<td>Supernus Pharmaceuticals</td>
<td>Neutral</td>
<td>9.34%</td>
<td>$173.14M</td>
<td>-4.27%</td>
</tr>
<tr>
<td>Ligand Pharmaceuticals</td>
<td>Buy</td>
<td>122.85%</td>
<td>$111.66M</td>
<td>13.19%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>公司</th>
<th>共識</th>
<th>收入增長</th>
<th>毛利潤</th>
<th>股本回報率</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prestige Consumer</td>
<td>買入</td>
<td>-3.41%</td>
<td>1.5158 億美元</td>
<td>2.29%</td>
</tr>
<tr>
<td>Tarsus Pharmaceuticals</td>
<td>跑贏大盤</td>
<td>146.68%</td>
<td>1.1039 億美元</td>
<td>-3.77%</td>
</tr>
<tr>
<td>Supernus Pharmaceuticals</td>
<td>中性</td>
<td>9.34%</td>
<td>1.7314 億美元</td>
<td>-4.27%</td>
</tr>
<tr>
<td>Ligand Pharmaceuticals</td>
<td>買入</td>
<td>122.85%</td>
<td>1.1166 億美元</td>
<td>13.19%</td>
</tr>
</tbody>
</table>
</div><p>Key Takeaway:</p>
<div class="lb-trans"><p>關鍵要點：</p>
</div><p>Prestige Consumer ranks at the bottom for Revenue Growth and Gross Profit, while it ranks in the middle for Return on Equity.</p>
<div class="lb-trans"><p>Prestige Consumer 在收入增長和毛利潤方面排名靠後，而在股本回報率方面排名中等。</p>
</div><h3>Get to Know Prestige Consumer Better</h3>
<div class="lb-trans"><h3>更好地瞭解 Prestige Consumer</h3>
</div><p>Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.</p>
<div class="lb-trans"><p>Prestige Consumer Healthcare 是最大的純粹非處方醫療保健提供商之一。它擁有多樣化的產品組合，涵蓋了細分消費健康類別中的領先品牌。Prestige 的主要品牌包括 Clear Eyes（緩解紅眼）、Dramamine（緩解暈動病）、Monistat（陰道抗真菌藥）和 Summer's Eve（女性衞生用品），其許多品牌在類別中享有領導地位，並獲得醫療專業人士的推薦。該公司主要在北美運營，約 85% 的總收入來自該地區，其餘銷售來自澳大利亞、新西蘭和某些亞洲市場。</p>
</div><h3>Breaking Down Prestige Consumer's Financial Performance</h3>
<div class="lb-trans"><h3>分析 Prestige Consumer 的財務表現</h3>
</div><p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<div class="lb-trans"><p><strong>市值分析：</strong> 公司的市值低於行業基準，反映出與同行相比規模較小。這一定位可能受到增長預期或運營能力等因素的影響。</p>
</div><p><strong>Negative Revenue Trend:</strong> Examining Prestige Consumer's financials over 3 months reveals challenges. As of 30 September, 2025, the company experienced a decline of approximately <strong>-3.41%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<div class="lb-trans"><p><strong>負面收入趨勢：</strong> 對 Prestige Consumer 的財務數據進行三個月的審查顯示出挑戰。截至 2025 年 9 月 30 日，該公司的收入增長約下降了 <strong>-3.41%</strong>，反映出頂線收益的減少。與同行相比，收入增長落後於行業同行。該公司的增長率低於醫療保健行業同行的平均水平。</p>
</div><p><strong>Net Margin:</strong> Prestige Consumer's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>15.4%,</strong> the company showcases strong profitability and effective cost management.</p>
<div class="lb-trans"><p><strong>淨利潤率：</strong> Prestige Consumer 的財務實力體現在其卓越的淨利潤率上，超過行業平均水平。該公司的淨利潤率達到 <strong>15.4%</strong>，展現出強大的盈利能力和有效的成本管理。</p>
</div><p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>2.29%,</strong> the company showcases effective utilization of equity capital.</p>
<div class="lb-trans"><p><strong>股本回報率（ROE）：</strong> 該公司的 ROE 表現突出，超過行業平均水平。其 ROE 達到 <strong>2.29%</strong>，展現出有效利用股本的能力。</p>
</div><p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>1.23%,</strong> the company showcases effective utilization of assets.</p>
<div class="lb-trans"><p><strong>資產回報率（ROA）：</strong> 該公司的 ROA 表現突出，超過行業平均水平。其 ROA 達到 <strong>1.23%</strong>，展現出有效利用資產的能力。</p>
</div><p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.57</strong>.</p>
<div class="lb-trans"><p><strong>債務管理：</strong> 該公司保持平衡的債務管理，債務與股本比率低於行業標準，達到 <strong>0.57</strong>。</p>
</div><p>To track all earnings releases for Prestige Consumer visit their earnings calendar on our site.</p>
<div class="lb-trans"><p>要跟蹤 Prestige Consumer 的所有財報發佈，請訪問我們網站的財報日曆。</p>
</div><p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>
<div class="lb-trans"><p><em>本文由 Benzinga 的自動內容引擎生成，並由編輯審核。</em></p>
</div>

普雷斯蒂奇品牌的消費者收益：前瞻